Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4918652 | 0.94 | TDP1 (0.50) | IDO1MEN1KMT2AHRH3SIGMAR1 | |
| SCHEMBL9021246 | 0.92 | TDP1 (0.53) | IDO1MEN1KMT2AHRH3SIGMAR1 | |
| SCHEMBL9021154 | 0.92 | TDP1 (0.53) | IDO1MEN1KMT2AHRH3SIGMAR1 | |
| SCHEMBL9021144 | 0.92 | TDP1 (0.53) | IDO1MEN1KMT2AHRH3SIGMAR1 | |
| SCHEMBL8500354 | 0.92 | TDP1 (0.53) | IDO1MEN1KMT2AHRH3SIGMAR1 | |
| SCHEMBL4922180 | 0.92 | IDO1 (0.55) | IDO1MEN1KMT2AHRH3LMNA | |
| SCHEMBL5978694 | 0.90 | IDO1 (0.53) | IDO1MEN1KMT2AHRH3LMNA | |
| SCHEMBL196951 | 0.89 | IDO1 (0.67) | IDO1MEN1KMT2AHRH3LMNA | |
| SCHEMBL9021596 | 0.88 | IDO1 (0.52) | IDO1MEN1KMT2AHRH3LMNA | |
| SCHEMBL9021621 | 0.88 | IDO1 (0.52) | IDO1MEN1KMT2AHRH3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102725269-B | synthetic intermediate of oxazole compound and preparation method thereof | OTSUKA PHARMA CO LTD | 2015-03-25 | — | — | CN | disclosed |
| EP-2644599-B1 | Method for preparing a 2-halo-4-nitroimidazole compound | OTSUKA PHARMA CO LTD (JP) | 2014-12-10 | — | — | EP | disclosed |
| EP-2528896-B1 | SYNTHETIC INTERMEDIATE OF OXAZOLE COMPOUND AND METHOD FOR PRODUCING THE SAME | OTSUKA PHARMA CO LTD (JP) | 2014-08-27 | — | — | EP | disclosed |
| US-8598358-B2 | Synthetic intermediate of oxazole compound and method for producing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-12-03 | — | — | US | disclosed |
| US-8552188-B2 | Epoxy compound and method for manufacturing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2644599-A1 | Method for preparing 1-substituted-4-nitroimidazole compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-02 | — | — | EP | disclosed |
| US-20130072683-A1 | EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-21 | — | — | US | disclosed |
| US-8344148-B2 | Epoxy compound and method for manufacturing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-01 | — | — | US | disclosed |
| EP-2528896-A1 | SYNTHETIC INTERMEDIATE OF OXAZOLE COMPOUND AND METHOD FOR PRODUCING THE SAME | Otsuka Pharmaceutical Co., Ltd. (JP) | 2012-12-05 | — | — | EP | disclosed |
| US-20120302757-A1 | SYNTHETIC INTERMEDIATE OF OXAZOLE COMPOUND AND METHOD FOR PRODUCING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-11-29 | — | — | US | disclosed |
| US-20040072690-A1 | Novel propionic acid derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-04-15 | — | — | US | disclosed |
| US-5607934-A | PREVENTING AND TREATING DISEASES CAUSED BY SUPEROXIDE RADICALS, NEPHRITIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-03-04 | — | — | US | disclosed |
| EP-0500853-B1 | PHENYLETHANOLAMINES, DRUGS CONTAINING THESE COMPOUNDS, AND A METHOD OF PREPARING THEM | THOMAE GMBH DR K (DE) | 1996-12-27 | — | — | EP | disclosed |
| CN-1112364-A | Piperazine derivatives and salts thereof | OTSUKA PHARMA CO LTD (JP) | 1995-11-22 | — | — | CN | disclosed |
| EP-0659182-A1 | PIPERAZINE DERIVATIVES AND SALTS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-06-28 | — | — | EP | disclosed |
| US-5393774-A | Antispasmodic agents | PIEPER HELMUT (DE) | 1995-02-28 | — | — | US | disclosed |
| WO-1995002593-A1 | PIPERAZINE DERIVATIVES AND SALTS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-01-26 | — | — | WO | disclosed |
| EP-0500853-A1 | PHENYLETHANOLAMINES, DRUGS CONTAINING THESE COMPOUNDS, AND A METHOD OF PREPARING THEM. | THOMAE GMBH DR K (DE) | 1992-09-02 | — | — | EP | disclosed |
| WO-1992004316-A1 | PHENYLETHANOLAMINES, DRUGS CONTAINING THESE COMPOUNDS, AND A METHOD OF PREPARING THEM | DR. KARL THOMAE GMBH (DE) | 1992-03-19 | — | — | WO | disclosed |
| US-4598155-A | 3(5-tetrazolyl)1,4-diaminoanthraquinones | CIBA-GEIGY CORPORATION (US) | 1986-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072690-A1 | Novel propionic acid derivatives | PNLIP, LIPC, GPR119 | IDO1 4434/4885MEN1 3338/4885KMT2A 3063/4885 |
| US-20120302757-A1 | SYNTHETIC INTERMEDIATE OF OXAZOLE COMPOUND AND METHOD FOR PRODUCING THE SAME | GLP1R, HBB, OXA1L | IDO1 1092/4885MEN1 2563/4885KMT2A 2496/4885 |
| US-20130072683-A1 | EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME | SQLE, CYP2E1, CYP1A1 | IDO1 1365/4885MEN1 2367/4885KMT2A 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.